Dataset from A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer

This is a randomized, Phase III, multicenter, open-label study designed to evaluate the
safety and efficacy of atezolizumab in combination with cisplatin or carboplatin + pemetrexed
compared with treatment with cisplatin or carboplatin + pemetrexed in participants who are
chemotherapy-naive and have Stage IV non-squamous NSCLC. Eligible participants will be
randomized by a 1:1 ratio into 2 groups: Arm A (Atezolizumab + Carboplatin or Cisplatin +
Pemetrexed) and Arm B (Carboplatin or Cisplatin + Pemetrexed). The study will be conducted in
two phases: Induction Phase and Maintenance Phase.